Literature DB >> 29755847

18F-FDG PET/CT findings in hepatosplenic Gamma-Delta T-cell lymphoma: case reports and review of the literature.

Michael W Cho1, Bennett B Chin2.   

Abstract

Hepatosplenic Gamma Delta T cell lymphoma (γδHSTL) is a rare, highly aggressive, and rapidly lethal T cell lymphoma which manifests 18F-FDG PET/CT findings that can mimic benign conditions. Patients with γδHSTL present with unexplained symptoms of a hematologic malignancy like the B symptoms of lymphoma including weight loss, fevers, and night sweats, as well as, splenomegaly and hepatomegaly. Thrombocytopenia, anemia, or neutropenia are also common due to spleen, liver and bone marrow involvement. The peripheral blood, however, typically does not show abnormal T cells. The clinical and 18F-FDG PET/CT findings are presented for 3 patients with γδHSTL. Patients with γδHSTL may have a normal 18F-FDG PET/CT or an 18F-FDG PET/CT with any combination of the three findings: splenomegaly with intense FDG uptake; hepatomegaly with increased FDG uptake; and diffuse, increased FDG uptake in the bone marrow. Importantly, lymphadenopathy is usually absent, and most patients show morphologically normal lymph nodes with normal FDG uptake. Due to the aggressive nature of the disease, γδHSTL is a critical diagnosis to consider in patients who present with clinical signs of suspected hematologic malignancy and variable 18F-FDG PET/CT findings. The absence of lymphadenopathy and normal FDG uptake in lymph nodes are typical pertinent negative findings that differentiate γδHSTL from other lymphomas. A bone or liver biopsy is frequently necessary to establish the diagnosis and should be recommended.

Entities:  

Keywords:  18F-FDG PET/CT; Hepatosplenic Gamma-Delta T-cell lymphoma; anemia; chemotherapy; hematology and oncology; hepatosplenomegaly; infection; myelodysplastic syndrome; non-Hodgkin lymphoma; pancytopenia

Year:  2018        PMID: 29755847      PMCID: PMC5944829     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  21 in total

1.  Diffuse bone marrow uptake on F-18 FDG PET in patients with myelodysplastic syndromes.

Authors:  Kentaro Inoue; Ken Okada; Hideo Harigae; Yasuyuki Taki; Ryoi Goto; Shigeo Kinomura; Shunsuke Kato; Tomohiro Kaneta; Hiroshi Fukuda
Journal:  Clin Nucl Med       Date:  2006-11       Impact factor: 7.794

2.  Intense FDG uptake in the spleen due to recent granulocyte-macrophage colony-stimulating factor administration: follow-up scan clarifying the situation.

Authors:  Sandip Basu; Nawab S Baghel
Journal:  J Cancer Res Ther       Date:  2011 Apr-Jun       Impact factor: 1.805

Review 3.  Challenges and new prospects in hepatosplenic γδ T-cell lymphoma.

Authors:  Marco Calvaruso; Alessandro Gulino; Salvatore Buffa; Carla Guarnotta; Giovanni Franco; Matilde Cacciatore; Maria Grazia Bonura; Vito Franco; Ada Maria Florena
Journal:  Leuk Lymphoma       Date:  2014-03-10

Review 4.  Hepatosplenic gamma-delta T-cell lymphoma.

Authors:  Andrés J M Ferreri; Silvia Govi; Stefano A Pileri
Journal:  Crit Rev Oncol Hematol       Date:  2011-11-01       Impact factor: 6.312

5.  Spleen in haematological malignancies: spectrum of imaging findings.

Authors:  S S Saboo; K M Krajewski; K N O'Regan; A Giardino; J R Brown; N Ramaiya; J P Jagannathan
Journal:  Br J Radiol       Date:  2011-11-17       Impact factor: 3.039

6.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

Authors:  Julie Vose; James Armitage; Dennis Weisenburger
Journal:  J Clin Oncol       Date:  2008-07-14       Impact factor: 44.544

Review 7.  Hepatosplenic γδ T-cell lymphoma: an overview.

Authors:  Koppany Visnyei; Michael L Grossbard; Ilan Shapira
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-08

Review 8.  Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.

Authors:  Karim Belhadj; Felix Reyes; Jean-Pierre Farcet; Herve Tilly; Christian Bastard; Regis Angonin; Eric Deconinck; Frederic Charlotte; Veronique Leblond; Eric Labouyrie; Pierre Lederlin; Jean-Francois Emile; Beatrice Delmas-Marsalet; Bertrand Arnulf; Elie-Serge Zafrani; Philippe Gaulard
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113

Review 9.  Radionuclide imaging of bone marrow disorders.

Authors:  Ali Agool; Andor W J M Glaudemans; Hendrikus H Boersma; Rudi A J O Dierckx; Edo Vellenga; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

10.  Progression of a hepatosplenic gamma delta T-cell leukemia/lymphoma on hyperCVAD/MTX and ara-C: literature review and our institutional treatment approach.

Authors:  Abhijit Saste; Javier Arias-Stella; Philip Kuriakose
Journal:  Clin Case Rep       Date:  2015-11-23
View more
  2 in total

Review 1.  Hepatosplenic T-cell lymphoma: a rare but challenging entity.

Authors:  Barbara Pro; Pamela Allen; Amir Behdad
Journal:  Blood       Date:  2020-10-29       Impact factor: 22.113

2.  18F-fluorodeoxyglucose positron emission tomography-based prediction for splenectomy in patients with suspected splenic lymphoma.

Authors:  Yingwei Hu; Weiyan Zhou; Siyuan Sun; Yihui Guan; Jiexian Ma; Yanhui Xie
Journal:  Ann Transl Med       Date:  2021-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.